OptiBiotix set for a strong 2019 as agreements convert into revenues

11:58 EDT 30 Apr 2019 | Proactive Investors

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara looks back on 2018 following the release of their full year results

Among some of the highlights in the period was a five-year deal with Akums Drugs and Pharmaceuticals to exclusively manufacture and supply supplements and drug products containing OptiBiotix’s LPLDL bacteria strain in India.

It also has an exclusive agreement with a US company for the LPLDL that carries six-figure milestone payments.

O'Hara says the raft of agreements signed are now starting to convert to revenues because of the lag period between signing and the start of cash coming in.

Original Article: OptiBiotix set for a strong 2019 as agreements convert into revenues


More From BioPortfolio on "OptiBiotix set for a strong 2019 as agreements convert into revenues"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...